Clinical Indications for Thrombopoietin and Thrombopoietin-receptor Agonists

Overview

Journal Transfus Med Hemother

Specialty Hematology

Date 2013 Nov 26

PMID 24273485

Citations 14

Authors

Bernhard Wormann

Affiliations

Soon will be listed here.

Abstract

Thrombocytopenia is a common hematologic disorder. Stimulation of thrombopoiesis may reduce the risk for thrombocytopenia-induced bleeding, prevent severe thrombocytopenia, and reduce the need for platelet transfusion. The key cytokine is thrombopoietin (TPO). It regulates proliferation and maturation of megakaryocytes as well as platelet production. TPO is synthesized in the liver. Development of TPO from the laboratory into a therapeutic tool has turned out to be an unexpected challenge. Clinical trials on first-generation thrombopoietic growth factors were stopped in 2001. At present, second-generation thrombopoiesis-stimulating agents have only been approved as orphan drugs for third-line therapy of patients with chronic immune thrombocytopenia. Larger groups in need are patients with myelodysplastic syndrome, chemotherapy-induced thrombocytopenia, other forms of hereditary and acquired bone marrow failure, hepatitis C infections, or liver cirrhosis.

Citing Articles

Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.

Gurumurthy G, Kisiel F, Gurumurthy S, Gurumurthy J J Oncol Pharm Pract. 2023; 31(1):4-11.

PMID: 38155484 PMC: 11771093. DOI: 10.1177/10781552231219003.

Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial.

Chakraborty S, Alam S, Sanyal M, Das T, Saha P, Sayem M EClinicalMedicine. 2020; 29-30:100624.

PMID: 33294822 PMC: 7691733. DOI: 10.1016/j.eclinm.2020.100624.

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment.

Bidika E, Fayyaz H, Salib M, Memon A, Gowda A, Rallabhandi B Cureus. 2020; 12(8):e9920.

PMID: 32968581 PMC: 7505620. DOI: 10.7759/cureus.9920.

Icaritin Provokes Serum Thrombopoietin and Downregulates Thrombopoietin/MPL of the Bone Marrow in a Mouse Model of Immune Thrombocytopenia.

Zhang K, Dai Z, Liu R, Tian F, Liu X, Sun Y Mediators Inflamm. 2018; 2018:7235639.

PMID: 30224899 PMC: 6129856. DOI: 10.1155/2018/7235639.

[Efficacy of recombinant human thrombopoietin combined with high-dose dexamethasone in the treatment of refractory immune thrombocytopenia in children].

Lu Y, Guan N, Meng Q, Li M, Liu Y, Wang Y Zhongguo Dang Dai Er Ke Za Zhi. 2018; 20(7):534-537.

PMID: 30022753 PMC: 7389201.

References

Cheng G, Saleh M, Marcher C, Vasey S, Mayer B, Aivado M . Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2010; 377(9763):393-402. DOI: 10.1016/S0140-6736(10)60959-2. View

Kantarjian H, Giles F, Greenberg P, Paquette R, Wang E, Gabrilove J . Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010; 116(17):3163-70. PMC: 3324162. DOI: 10.1182/blood-2010-03-274753. View

Townsley D, Desmond R, Dunbar C, Young N . Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol. 2013; 98(1):48-55. PMC: 4144663. DOI: 10.1007/s12185-013-1352-6. View

Wang E, Lyons R, Larson R, Gandhi S, Liu D, Matei C . A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol. 2012; 5:71. PMC: 3520696. DOI: 10.1186/1756-8722-5-71. View

Jenkins J, Williams D, Deng Y, Uhl J, Kitchen V, Collins D . Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739-41. DOI: 10.1182/blood-2006-11-057968. View

Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F . Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008; 48(6):1000-7. DOI: 10.1016/j.jhep.2008.03.009. View

Kantarjian H, Fenaux P, Sekeres M, Becker P, Boruchov A, Bowen D . Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2009; 28(3):437-44. DOI: 10.1200/JCO.2009.24.7999. View

Gardner K, Mathe S, Sahu S . Leukaemic transformation with romiplostim. Br J Haematol. 2012; 158(2):153. DOI: 10.1111/j.1365-2141.2012.09194.x. View

Bussel J, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L . Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9664):641-8. DOI: 10.1016/S0140-6736(09)60402-5. View

10.

Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A . c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97(1):139-46. DOI: 10.1182/blood.v97.1.139. View

11.

Trautmann K, Jakob C, von Grunhagen U, Schleyer E, Brummendorf T, Siegert G . Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia. Thromb Haemost. 2012; 108(2):397-8. DOI: 10.1160/TH12-02-0121. View

12.

Kaushansky K, Lok S, Holly R, Broudy V, Lin N, BAILEY M . Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994; 369(6481):568-71. DOI: 10.1038/369568a0. View

13.

Kantarjian H, Giles F, List A, Lyons R, Sekeres M, Pierce S . The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007; 109(9):1705-14. DOI: 10.1002/cncr.22602. View

14.

Foster D, Sprecher C, Grant F, Kramer J, Kuijper J, Holly R . Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1994; 91(26):13023-7. PMC: 45573. DOI: 10.1073/pnas.91.26.13023. View

15.

Kuter D, Beeler D, Rosenberg R . The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994; 91(23):11104-8. PMC: 45175. DOI: 10.1073/pnas.91.23.11104. View

16.

Lok S, Kaushansky K, Holly R, Kuijper J, Oort P, Grant F . Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994; 369(6481):565-8. DOI: 10.1038/369565a0. View

17.

Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther M . The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190-207. DOI: 10.1182/blood-2010-08-302984. View

18.

Wiestner A, Schlemper R, van der Maas A, Skoda R . An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998; 18(1):49-52. DOI: 10.1038/ng0198-49. View

19.

Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, GOOD R . Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A. 1999; 96(6):3132-6. PMC: 15907. DOI: 10.1073/pnas.96.6.3132. View

20.

Stasi R, Bosworth J, Rhodes E, Shannon M, Willis F, Gordon-Smith E . Thrombopoietic agents. Blood Rev. 2010; 24(4-5):179-90. DOI: 10.1016/j.blre.2010.04.002. View